Background and objective The utility of prostate radiotherapy (RT) is unclear in men with
metastatic hormone-sensitive prostate cancer (mHSPC) receiving intensified systemic …

Multiple studies have demonstrated the importance of androgen receptor (AR) splice
variants (SVs) in the progression of prostate cancer to the castration-resistant phenotype …

Two randomized controlled trials recently demonstrated an overall survival benefit with
triplet therapy (androgen receptor axis–targeted agent [ARAT]+ docetaxel+ androgen …

Purpose: To perform a systematic review and network meta-analysis to compare the efficacy
and safety of currently available docetaxel-based systemic triplet therapies for metastatic …

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has
evolved rapidly in the past decade with the approval of several life-prolonging therapies …

Purpose: To conduct a systematic review and network meta-analysis (NMA) to compare the
efficacy of currently available combination therapies in patients with metastatic hormone …

Prostate cancer is the first most frequent cancer in men worldwide, with over 250,000
estimated new cases diagnosed in 2021 [1]. Primary treatment modalities mostly include …

Simple Summary In this exploratory analysis of a randomized controlled trial, we found that
dynamic changes in simple laboratory-based markers such as prostate-specific antigen …

Androgen receptor (AR) signaling is essential in prostate cancer treatment. For many years,
androgen deprivation therapy (ADT) has been primarily applied to manage advanced …

In recent years, several systemic therapies have been introduced for metastatic hormone-
sensitive prostate cancer, including androgen deprivation therapy (ADT) combined with …